Drugs / hPTH (1-84)
hPTH (1-84)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00005005 | Oct 1999 → Nov 2007 | osteoporosis | Dennis Black | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hPTH (1-84) | “The PaTH study is a 2-year, multicenter, double-blind, placebo-controlled trial to test the efficacy of combining hPTH (1-84) and alendronate for treating osteoporosis in...” NCT00005005 ↗ |
| Known as | parathyroid hormone | “daily treatment with parathyroid hormone (1-84) (100 microg; 119 women), alendronate (10 mg; 60 women), or both (59 women)” PMID 14500804 ↗ Sep 2003 |
| Known as | parathyroid hormone (1-84) | “daily treatment with parathyroid hormone (1-84) (100 microg; 119 women), alendronate (10 mg; 60 women), or both (59 women)” PMID 14500804 ↗ Sep 2003 |
| Known as | PTH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005005 ↗ |
| Route | Subcutaneous | “INTERVENTION: Subjects were randomized to sc PTH (1-84), 100 mug/d (119 women), for 1 yr.” PMID 16449339 ↗ Jan 2006 |